{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282680467580288.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.11553/antibiotics1968b.27.643"}},{"identifier":{"@type":"COI","@value":"1:CAS:528:DyaE2MXksFensro%3D"}},{"identifier":{"@type":"PMID","@value":"4218271"}},{"identifier":{"@type":"NDL_BIB_ID","@value":"7494681"}},{"identifier":{"@type":"URI","@value":"http://id.ndl.go.jp/bib/7494681"}},{"identifier":{"@type":"URI","@value":"https://ndlsearch.ndl.go.jp/books/R000000004-I7494681"}},{"identifier":{"@type":"NAID","@value":"130004392817"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/1975046901"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"en","@value":"MICROBIOLOGICAL STUDIES ON THE COMBINATION EFFECT OF RIFAMPICIN AND NALIDIXIC ACID"},{"@language":"ja","@value":"抗生物質Rifampicinと合成化学療法剤Nalidixic acidとの併用効果に関する細菌学的研究"},{"@language":"ja-Kana","@value":"コウセイ ブッシツ Rifampicin ト ゴウセイ カガク リョウホウザイ Nalidixic acid ト ノ ヘイヨウ コウカ ニ カンスル サイキンガクテキ ケンキュウ"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"Rifampicin (RFP), an antibiotic active against gram-positive bacteria including tubercule bacilli and gram-negative bacteria, has some weak points such as appearance of natural resistance in many bacteria, rapid development of resistance <I>in vitro, etc</I>.<BR>In trials on the combination of RFP with various chemotherapeutics in order to overcome these weak points it was found that a combination of RFP and nalidixic acid (NA) showed strong synergism in some bacteria and suppression of the <I>in vitro</I> development of resistance.<BR>A proper combination ratio of RFP and NA seemed to be 1: 4 from the results of <I>in vitro</I> and <I>in vivo</I> studies.<BR>The acute toxicity of this combination was approximately same as that of NA alone in mice.<BR>Colorimetry of cellular compornents revealed that the increase of DNA was more markedly inhibited in the cells of <I>E. coli</I> NIHJ treated with this combination than it was in the cells treated with NA alone."},{"@language":"ja","@value":"Rifampicin (RFP) は, 1957年イタリアのLepetit社において放線菌<I>Streptomyces mediterranei</I>から分離されたRifamycin SVの誘導体である. Rifamycin SVについては, すでに第11回日本化学療法学会総会 (大阪) の新薬シンポジウムとして, 基礎, 臨床面から検討が加えられたが, 生体内抗菌力が試験管内抗菌力と平行しなかつた点, 臨床適用時の注射局所の疼痛など問題点が多く, 我国ではついに日の目をみることができなかつた抗生物質である1). ところが, 10年後の1967年Rifampicinが半合成抗生物質として再登揚し, 優れた生体内効果や経口投与による有効性, 結核菌や1部のウイルスにまで有効なことなど, その面目を一新した成績が報告されている2, 3, 4, 5). 我々の教室においても, このRFPの細菌学的基礎研究をおこない, すでに一部報告をおこなつているが, RFPは<I>in vitro</I>においてGram陽性菌, Gram陰性球菌, 結核菌に対して非常に強い抗菌力を示すが, 大腸菌をはじめGram陰性桿菌に対する抗菌力は比較的弱く, これらの成績はマウス実験的感染症における治療実験の成績とよく一致していた5). 一方, RFPの抗菌作用の型式 (Growth curveで検討) については, 著明な殺菌作用 (Bactericidalaction) であることもみとめているが, この薬剤の大きな欠点として, <I>in vitro</I>での耐性獲得が非常に急速であり, その原因として自然耐性細胞の出現が考えられる. 1968年McCABEらは, Skip tubeという現象 (液体希釈法でRFPのMICを測定したばあいにMIC以上の薬剤を含む試験管内に, まれに菌の増殖がみとめられること) を発見し, RFPに対する耐性ブドウ球菌の出現率を報告している6). 今回, 我々がRFPに対する耐性を防止または遅延する目的で併用したNalidixic acid (NA) は, 1962年米国Sterling-Winthrop社において合成されたNaphthyridine誘導体の抗菌剤である. 本剤の化学療法剤としての価値については, 多くの研究者によつて詳細に検討され, 現在各国でGram陰性桿菌による腸管系, 尿路系感染症などの治療に使用されている7, 8, 9).<BR>NAは, Gram陰性桿菌に対して, MIC以上の濃度では殺菌作用は比較的強いが, RFPと同様に試験管内耐性獲得がかなり早い欠点をもつている. 我々は, RFPの高度耐性菌の出現またはこれによると考えられる薬剤耐性化を抑制または遅延する目的で, RFPと種々の抗菌剤との併用を検討したところ, 2, 3の菌種に対して, NAとの併用において最も優れた協力効果を示すとともに, 興味ある知見が得られたので報告する."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410009221734029057","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256770157"}],"foaf:name":[{"@language":"en","@value":"ISHIYAMA MASAMITSU"},{"@language":"ja","@value":"石山 正光"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Microbiology, Kyoto College of Pharmacy"},{"@language":"ja","@value":"京都薬科大学微生物学教室"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221734029056","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256770158"}],"foaf:name":[{"@language":"en","@value":"NAKAZAWA SHOZO"},{"@language":"ja","@value":"中沢 昭三"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Microbiology, Kyoto College of Pharmacy"},{"@language":"ja","@value":"京都薬科大学微生物学教室"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03682781"},{"@type":"LISSN","@value":"03682781"},{"@type":"EISSN","@value":"21865477"},{"@type":"NDL_BIB_ID","@value":"000000000264"},{"@type":"ISSN","@value":"03682781"},{"@type":"NCID","@value":"AN00002626"}],"prism:publicationName":[{"@language":"en","@value":"The Japanese Journal of Antibiotics"},{"@language":"ja","@value":"The Japanese Journal of Antibiotics"},{"@language":"en","@value":"JJA"},{"@language":"en","@value":"Jpn J Antibiot."},{"@language":"en","@value":"Jpn. J. Antibiotics"},{"@language":"ja","@value":"Jpn. J. Antibiotics"},{"@language":"ja","@value":"JJA"}],"dc:publisher":[{"@language":"en","@value":"Japan Antibiotics Research Association"},{"@language":"ja","@value":"公益財団法人 日本感染症医薬品協会"}],"prism:publicationDate":"1974","prism:volume":"27","prism:number":"5","prism:startingPage":"643","prism:endingPage":"652"},"url":[{"@id":"http://id.ndl.go.jp/bib/7494681"},{"@id":"https://ndlsearch.ndl.go.jp/books/R000000004-I7494681"},{"@id":"https://search.jamas.or.jp/link/ui/1975046901"}],"availableAt":"1974","dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:1001875088"},{"@type":"NDL_SEARCH","@value":"oai:ndlsearch.ndl.go.jp:R000000004-I7494681"},{"@type":"PUBMED","@value":"4218271"},{"@type":"CIA","@value":"130004392817"}]}